Drugs / P-IL-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05829057 | May 2023 → Dec 2024 | esophageal cancer, liver cancer, ovarian cancer, small cell lung carcinoma +1 | Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P-IL-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05829057 ↗ |
| Modality | Cell therapy | “Platelet-coupled IL-2 Cell Injection (P-IL-2)” NCT05829057 ↗ |
| Route | Intravenous | “P-IL-2 injection was injected intravenously” NCT05829057 ↗ |